icon
icon
icon
icon
Upgrade
Upgrade
Current data has a 15-minute delay. Please / to get real-time quotes.
icon
Key StatisticsCurrency:USD
EPS(TTM)
-1.22
P/E(TTM)
-0.33
BVPS
0.33
P/B
0.93
Revenue(2024 Q4)
--
YoY
--
Net Income(2024 Q4)
-2.36M
YoY
70.11%
Gross Margin(TTM)
--
Net Margin(TTM)
--
ROE(TTM)
--
Debt ratio
38.46%
Dividend Yield(TTM)
--
Payout Ratio
--
Unveiling the company's Dividend Strategy

Profile
Cellectar Biosciences, Inc.
A late-stage biopharmaceutical company focused on targeted treatments for cancer
Cellectar Biosciences, Inc., formerly known as Novelos Therapeutics, Inc., was founded in Delaware in June 1996. On February 11, 2014, the company changed its name to its current name. The company is a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of cancer therapies. The company's core objective is to utilize proprietary phospholipid ether drug conjugate delivery platforms to develop PDCs that are designed to specifically target cancer cells and provide better efficacy and better safety due to fewer off-target effects.
More details
Related Sections
  • P
    Pharmaceuticals+0.62%
Pharma Tracker
No Upcoming Event
Stay ahead with our Pharma Tracker: Monitor the latest developments in new drug research, financial health, and FDA updates for the company
More details
Revenue BreakdownCurrency:USD

No Data

More details
Major shareholders
Entities Affiliated with Rosalind Advisors, Inc.
More details
DividendsCurrency:USD

No Data

Net Income Attributable to Parent
Total Cash Dividends
Payout Ratio
Unveiling the company's Dividend Strategy

Institutional Holdings
Totally
29
institutions reported their ownerships on
CLRB
Institutional Holding Ratio
Price
Insider Transactions
Net increase
Net decrease
Price
More details
Stock split and consolidation
Declaration Date
Plan
Ex-Div Date

Jul 22, 2022

10->1

Jul 22, 2022

More details
Executive Profile
J
James Caruso
President, Chief Executive Officer and Director
D
Dov Elefant
Vice President and Chief Financial Officer
J
Jarrod Longcor
Chief Business Officer
J
John E. Friend II
Vice President and Chief Medical Officer
More details
You Can Understand Stocks with AI.
Why NVDA surged 16.40%?
Because it
fork
logo
AInvest
Aime Coplilot
Invest Smarter With AI Power.
Open App